Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanoxel + Herzuma
- Development stage
- Unknown
- Lead developer
- Samsung Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Nanoxel + Herzuma is a combination chemotherapy regimen being evaluated for the treatment of HER2-positive metastatic salivary duct carcinoma. The regimen consists of Nanoxel, a polymeric micelle formulation of the taxane paclitaxel, and Herzuma (trastuzumab-pkrb), a biosimilar monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). Paclitaxel works by binding to tubulin and stabilizing microtubules, which inhibits mitosis and leads to cell death. Herzuma binds to the extracellular domain of the HER2 receptor, inhibiting downstream signaling pathways and recruiting immune effector cells to mediate antibody-dependent cellular cytotoxicity (ADCC). This combination is being studied in a Phase II clinical trial led by Samsung Medical Center to address the high prevalence of HER2 overexpression in salivary duct carcinomas, a rare and aggressive malignancy.
- Brand names
- NanoxelHerzuma
- Other names
- paclitaxel + trastuzumab-pkrbNanoxel plus HerzumaNanoxel and Herzuma
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Nanoxel + Herzuma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanoxel + Herzuma.